author-photo

Bob T. Li

Memorial Sloan Kettering Cancer Center
University of Sydney
Cornell University

180

Papers

5549

Citations

Citation Trend

Filter By

Papers (180) Sort By

Journal Conference Others

Modification of Pathological T Classification for Non-small Cell Lung Cancer with Visceral Pleural Invasion: Data from 1,055 Cases of Cancers 3 cm or Less.

2021 Chest
Show All
- Source
- Cite
- Save
Citations (0)
Durée du bénéfice clinique et analyse des biomarqueurs chez les patients (pts) atteints d’un cancer du poumon non à petites cellules avancées (CPNPC) traité avec l’AMG 510 (sotorasib)

2021 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT181: Clinical validation of plasma cell-free DNA (cfDNA) sequencing in the phase 2 trial of sotorasib in patients (pts) with KRAS p.G12C mutated NSCLC

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.

2021 Genome Medicine
Show All
- Source
- Cite
- Save
Citations (5)
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)